TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07745504: A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Sponsor: Novo Nordisk A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 285 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$11,361,704

Rescue Site Savings

+$7,495,896

Unlock Full NCT07745504 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07745504 Rescue Dossier →